STTK Stock Summary and Trading Ideas (Shattuck Labs | NASDAQ:STTK)

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Shattuck Labs trades on the NASDAQ stock market under the symbol STTK.

As of December 26, 2025, STTK stock price climbed to $3.35 with 218,248 million shares trading.

STTK has a beta of 3.06, meaning it tends to be more sensitive to market movements. STTK has a correlation of 0.27 to the broad based SPY ETF.

STTK has a market cap of $160.46 million. This is considered a Micro Cap stock.

In the last 3 years, STTK traded as high as $11.76 and as low as $.69.

The top ETF exchange traded funds that STTK belongs to (by Net Assets): VTI, VXF, QQQS, AVSC.

STTK has outperformed the market in the last year with a price return of +201.8% while the SPY ETF gained +16.0%. STTK has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +46.9% and +8.1%, respectively, while the SPY returned +4.6% and +1.5%, respectively.

STTK support price is $3.08 and resistance is $3.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STTK shares will trade within this expected range on the day.